NDAORALTABLET, EXTENDED RELEASE
Approved
May 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
TEPANIL TEN-TAB (diethylpropion hydrochloride) by Teva is clinical pharmacology diethylpropion hydrochloride is a sympathomimetic amine with some pharmacologic activity similar to that of the prototype drugs of this class used in obesity, the amphetamines. Approved for the management of exogenous obesity, higher. First approved in 1977.
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEPANIL TEN-TAB is a sympathomimetic amine (diethylpropion hydrochloride) extended-release tablet indicated for management of exogenous obesity. It works through central nervous system stimulation and appetite suppression, though the exact mechanism of weight loss is not fully established.
LOE Approaching
As an older anorectic approaching loss of exclusivity with moderate competitive pressure (30%), TEPANIL TEN-TAB likely operates with a lean, maintenance-focused team focused on sustaining volume against generic erosion.
Mechanism of Action
CLINICAL PHARMACOLOGY Diethylpropion hydrochloride is a sympathomimetic amine with some pharmacologic activity similar to that of the prototype drugs of this class used in obesity, the amphetamines. Actions include some central nervous system stimulation and elevation of blood pressure. Tolerance…
Worked on TEPANIL TEN-TAB at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.